This announcement is a separate document:
海普瑞：国投证券股份有限公司关于深圳证监局对深圳市海普瑞药业集团股份有限公司采取责令改正措施决定的临时受托管理事务报告
Haipuri: Report of SDIC Securities Co., Ltd. on the temporary fiduciary management affairs of the Shenzhen Securities Regulatory Bureau\'s decision to order corrective measures against Shenzhen Haipuri Pharmaceutical Group Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.